Recent advances in ameloblastoma management signal important practice implications for oral and maxillofacial surgeons. First, molecular profiling of recurrent tumours can identify specific pathway dysregulation—such as Wnt–β-catenin signalling abnormalities—that may be therapeutically targetable, shifting decision-making from purely anatomical considerations to biological insights.
Second, genetic analysis now enables personalized treatment selection, allowing clinicians to identify patients who may benefit from precision medicine approaches rather than additional surgical intervention. Third, these advances demonstrate that precision medicine is expanding beyond traditional surgical specialties into oral and maxillofacial surgery, improving outcomes for complex, recurrent cases.
For practitioners managing ameloblastoma patients, genetic testing of recurrent tumours should be considered as part of comprehensive treatment planning, particularly when surgical options are limited by anatomy or prior intervention.
Was this article helpful?
